FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2558292460> ?p ?o ?g. }

• W2558292460 endingPage "781" @default.
• W2558292460 startingPage "780" @default.
• W2558292460 abstract "To the Editor: We read with great interest the manuscript by Cardenas et al. entitled “Plasma Resuscitation Promotes Coagulation Homeostasis Following Shock-Induced Hypercoagulability” and published in this journal (1). The reported study showed that, compared with with Ringer lactate, resuscitation with fresh frozen plasma (FFP) reduced thrombin generation, reduced transfusion volume, and improved metabolic indicators of shock. The authors considered plasma resuscitation to be superior and emphasized that FFP reduces the risk of both consumptive coagulopathy and thromboembolic events. Thus, increasing thrombin generation is not considered a priority in the management of trauma-induced coagulopathy any more. Thrombin generation is typically upregulated in response to trauma (1, 2). Consequently, the emphasis now is on balanced resuscitation, either with predefined ratios of allogeneic blood products (e.g., 1:1:1 for plasma, red blood cells, and platelets) (3) or with a concentrate-based approach where point-of-care coagulation monitoring is used to tailor treatment to the patient's specific needs (4). This represents a transformation from the prevailing view 10 to 15 years ago. In that era, a “thrombin burst” (term first used in the literature in 1994 (5)) was considered to be beneficial in trauma patients. Accordingly, it was thought that recombinant activated factor VII (rFVIIa) could play a key role in managing trauma-induced coagulopathy and interest in this treatment gained considerable momentum (6). In layman's terms, our community had jumped onto the thrombin burst rocket but, in contrast, it is now on the balanced train! What triggered the transformation? The principal issue was safety: reports of thromboembolic complications in patients treated with rFVIIa began to emerge (7). The effectiveness of rFVIIa in the management of trauma may also be questioned. For example, in two randomized placebo-controlled trials, rFVIIa had no significant effects versus placebo on mortality (6, 8). While there remains a possible role for thrombin-generating drugs in trauma, the extent to which thrombin generation should be augmented is to be confirmed. The effectiveness of rFVIIa is considered to be unproven, and there is little evidence to support the use of prothrombin complex concentrates (PCCs) (9). Accordingly, the use of thrombin-generating drugs is restricted to specific situations. One approach is to use recombinant activated factor VII (rFVIIa) to “jump-start” coagulation when there is insufficient time to administer allogeneic blood products. Another approach is to use PCCs as part of coagulation factor concentrate-based treatment; PCCs are used second-line, for patients in whom fibrinogen supplementation has been performed as needed (10). The transformation in our views on managing trauma-induced coagulopathy is philosophically interesting. Our job as scientists is to appraise the available evidence impartially and treat our patients with the aim of optimizing clinical outcomes. In the early days of using rFVIIa for trauma, it could be argued that our community responded too quickly to the apparent benefits of this treatment. Over the longer term, the weight of evidence has led to a more considered approach where the potential benefits and harms of each intervention receive due consideration." @default.
• W2558292460 created "2016-12-08" @default.
• W2558292460 creator A5009704900 @default.
• W2558292460 creator A5044191999 @default.
• W2558292460 creator A5070424068 @default.
• W2558292460 date "2017-06-01" @default.
• W2558292460 modified "2023-09-26" @default.
• W2558292460 title "Is “Thrombin Burst” Now the Worst Option in Trauma?" @default.
• W2558292460 cites W190709734 @default.
• W2558292460 cites W2001894057 @default.
• W2558292460 cites W2045844558 @default.
• W2558292460 cites W2126420535 @default.
• W2558292460 cites W2133226878 @default.
• W2558292460 cites W2140699529 @default.
• W2558292460 cites W2163061022 @default.
• W2558292460 cites W2165755420 @default.
• W2558292460 cites W2188185117 @default.
• W2558292460 doi "https://doi.org/10.1097/shk.0000000000000808" @default.
• W2558292460 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27918371" @default.
• W2558292460 hasPublicationYear "2017" @default.
• W2558292460 type Work @default.
• W2558292460 sameAs 2558292460 @default.
• W2558292460 citedByCount "3" @default.
• W2558292460 countsByYear W25582924602017 @default.
• W2558292460 countsByYear W25582924602020 @default.
• W2558292460 countsByYear W25582924602021 @default.
• W2558292460 crossrefType "journal-article" @default.
• W2558292460 hasAuthorship W2558292460A5009704900 @default.
• W2558292460 hasAuthorship W2558292460A5044191999 @default.
• W2558292460 hasAuthorship W2558292460A5070424068 @default.
• W2558292460 hasConcept C126322002 @default.
• W2558292460 hasConcept C141071460 @default.
• W2558292460 hasConcept C177713679 @default.
• W2558292460 hasConcept C2777292125 @default.
• W2558292460 hasConcept C2778165595 @default.
• W2558292460 hasConcept C2778382381 @default.
• W2558292460 hasConcept C2778589496 @default.
• W2558292460 hasConcept C2778961111 @default.
• W2558292460 hasConcept C2779936836 @default.
• W2558292460 hasConcept C2781300812 @default.
• W2558292460 hasConcept C42219234 @default.
• W2558292460 hasConcept C66112548 @default.
• W2558292460 hasConcept C71924100 @default.
• W2558292460 hasConcept C89560881 @default.
• W2558292460 hasConceptScore W2558292460C126322002 @default.
• W2558292460 hasConceptScore W2558292460C141071460 @default.
• W2558292460 hasConceptScore W2558292460C177713679 @default.
• W2558292460 hasConceptScore W2558292460C2777292125 @default.
• W2558292460 hasConceptScore W2558292460C2778165595 @default.
• W2558292460 hasConceptScore W2558292460C2778382381 @default.
• W2558292460 hasConceptScore W2558292460C2778589496 @default.
• W2558292460 hasConceptScore W2558292460C2778961111 @default.
• W2558292460 hasConceptScore W2558292460C2779936836 @default.
• W2558292460 hasConceptScore W2558292460C2781300812 @default.
• W2558292460 hasConceptScore W2558292460C42219234 @default.
• W2558292460 hasConceptScore W2558292460C66112548 @default.
• W2558292460 hasConceptScore W2558292460C71924100 @default.
• W2558292460 hasConceptScore W2558292460C89560881 @default.
• W2558292460 hasIssue "6" @default.
• W2558292460 hasLocation W25582924601 @default.
• W2558292460 hasLocation W25582924602 @default.
• W2558292460 hasOpenAccess W2558292460 @default.
• W2558292460 hasPrimaryLocation W25582924601 @default.
• W2558292460 hasRelatedWork W1496129656 @default.
• W2558292460 hasRelatedWork W1566935349 @default.
• W2558292460 hasRelatedWork W1897057798 @default.
• W2558292460 hasRelatedWork W1964319357 @default.
• W2558292460 hasRelatedWork W1972495894 @default.
• W2558292460 hasRelatedWork W1993483465 @default.
• W2558292460 hasRelatedWork W2005358181 @default.
• W2558292460 hasRelatedWork W2046564088 @default.
• W2558292460 hasRelatedWork W2058953676 @default.
• W2558292460 hasRelatedWork W991737953 @default.
• W2558292460 hasVolume "47" @default.
• W2558292460 isParatext "false" @default.
• W2558292460 isRetracted "false" @default.
• W2558292460 magId "2558292460" @default.
• W2558292460 workType "article" @default.